The Epstein Barr virus (EBV) is an oncogenic herpesvirus that is intimately involved in a number of malignancies in humans. The genetic basis of EBV associated oncogenesis is the concerted action of EBV latency associated genes and varying cellular genetic alterations. In immuno-competent individuals only minimal EBV latency gene expression can be tolerated due to the immunogeneticity of several EBV encoded latency gene products. In AIDS patients, however, expression of the full repertoire of latency genes (referred to as type III latency) can sometimes be tolerated and expression of these genes provide many essential elements of tumor cell development. In this setting, fewer cellular genetic alterations are required to give rise to malignant cell populations and this probably partly explains the greatly increased susceptibility of AIDS patients to EBV associated non-Hodgkin's lymphomas. The cellular microRNA, miR-155, is one of the most highly implicated microRNAs in cancer. miR-155 is induced by the EBV type III latency program (but not the type I latency program) suggesting a possible role for miR-155 in modulating type III latency signal transduction. Further evidence that miR-155 signaling is relevant to herpesvirus biology has been provided by Rolf Renne's lab and by Bryan Cullen's lab who both showed recently that the Kaposi's Sarcoma Herpes virus (KSHV) encodes a functional homologue of miR- 155. Two mouse miR-155 knock out papers recently showed that miR-155 is important for B cell activation responses following immune challenge. We hypothesize that induction of miR-155 by EBV type III latency plays a role in facilitating EBV mediated B cell activation and that miR-155 modulates signal transduction pathways that contribute to EBV associated maligancies in AIDS patients.
EBV is associated with a number of human cancers including nasopharyngeal carcinoma, Hodgkin's lymphoma, Burkitt's lymphoma as well as a number of B-cell lymphomas in AIDS patients. Our studies are aimed at addressing the role of an oncogenic cellular microRNA, miR-155, that is induced by EBV latency genes expressed in AIDS associated malignancies.
|Striker, Rob; Mehle, Andrew (2014) Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses. PLoS Pathog 10:e1004428|
|Martin, Elizabeth C; Rhodes, Lyndsay V; Elliott, Steven et al. (2014) microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Mol Cancer 13:229|
|Xu, Guorong; Strong, Michael J; Lacey, Michelle R et al. (2014) RNA CoMPASS: a dual approach for pathogen and host transcriptome analysis of RNA-seq datasets. PLoS One 9:e89445|
|Strong, Michael J; Lin, Zhen; Flemington, Erik K (2014) Expanding the conversation on high-throughput virome sequencing standards to include consideration of microbial contamination sources. MBio 5:e01989|
|O'Grady, Tina; Cao, Subing; Strong, Michael J et al. (2014) Global bidirectional transcription of the Epstein-Barr virus genome during reactivation. J Virol 88:1604-16|
|Martin, Elizabeth C; Elliott, Steven; Rhodes, Lyndsay V et al. (2014) Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Mol Carcinog 53:38-48|
|Lin, Zhen; Wang, Xia; Strong, Michael J et al. (2013) Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. J Virol 87:1172-82|
|Strong, Michael J; O'Grady, Tina; Lin, Zhen et al. (2013) Epstein-Barr virus and human herpesvirus 6 detection in a non-Hodgkin's diffuse large B-cell lymphoma cohort by using RNA sequencing. J Virol 87:13059-62|
|Fang, Zhide; Du, Ruofei; Edwards, Andrea et al. (2013) The sequence structures of human microRNA molecules and their implications. PLoS One 8:e54215|
|Concha, Monica; Wang, Xia; Cao, Subing et al. (2012) Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J Virol 86:1458-67|
Showing the most recent 10 out of 18 publications